J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer study

Johnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of surgery.

The trial showed that patients given Erleada experienced a 20% lower risk of metastasis or death compared with standard care. This relative risk reduction was highlighted as a promising signal for improving outcomes in this patient group.

Analysts noted that while the result is encouraging, the data are from an early‑stage trial and further research is needed to confirm long‑term benefits and safety. The company indicated that additional studies are planned to address these questions.